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Induced Hypotension for Middle Ear Surgery
Hemostasis in middle ear surgery is a difficult state lo define, for surgeons vary greatly in their requirements. From an anTsthetic viewpoint there are many techniques employed to meet these requirements, all of which give satisfaction most of the time. While appreciating and acknowledging the fact that in some hands adequate operating conditions can be produced without it, this paper briefly discusses some aspects of induced hypotension as a method of producing the desired hemostasis.
Any discourse on induced hypotension would be incomplete without first a plea for meticulous attention to basic anesthetic techniques. It is only with a background of a stable level of anesthesia, adequate oxygenation and suitable positioning of the patient that induced hypotension should be contemplated.
Certain phases of microsurgical techniques require more meticulous hTmostasis than others, but regrettably it is not possible to provide such a degree of control over bleeding as to offer these fine variations. An attempt must be made to produce a period of hypotension to a level of blood pressure that will produce haemostasis, extending it to include all the various microsurgical manipulations. In any case, there is much to be said for a smooth lowering of blood pressure with its maintenance at subhaemorrhagic levels, rather than for a fluctuating field which might inadvertently slip out of control at a crucial phase.
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With these requirements, the anesthetist will need an agent for the induction of hypotension which is potent, predictable, and with rapid recovery if he is to use the technique in successive cases.
Until very recently the agent of choice seemed to be trimetaphan camsylate, which offered the nearest approach to these requirements. However, it has certain disadvantages, the most obvious being tachyphylaxis. This necessitates the use of stronger solutions of the drug than would otherwise be desirable. The result of the use of such potent drip strengths is the tendency to a more profound fall in blood pressure than is necessary, and an extension in the time taken for the blood pressure to return to its previous level.
It also has the disadvantages of histamine release, precluding its use in asthmatics, and high cost.
Recently, interest has been diverted (Jones & Cole 1968) towards another drug, sodium nitroprusside, for the production of hypotension. This lowers the blood pressure by producing peripheral vasodilatation, as does the ganglion blocker trimetaphan camsylate, but animal experiment has shown the effect, unlike that of trimetaphan, to be the result of a direct action on the vessel wall, independent of autonomic innervation (Page et al. 1955 ). This action is thus similar to that of the nitrites, but the nitroprusside effect is many times more potent.
The return of blood pressure to normal levels following its administration is dependent on destruction of the drug which occurs very rapidly and necessitates the use of a continuous drip for its administration. The evanescent action of sodium nitroprusside is due to the active radical 1224 Proc. roy. Soc. Med. Volume 64 December 1971 42 Table 1 Guidelines for use of sodium nitroprusside Sodium nitroprusside drip strength 50 mg/500 ml 25 mg/500 ml 10 mg/500 ml (0 01%) (0005%) (0-002%)
Males
Up to 30 years 30-50 years 50 years and over Females Up to 20 years 2040 years 40 years and over being destroyed by non-enzymatic sulphydryl linkage in the red cells and other tissues. The cyanogen thus produced is altered to thiocyanate, the change being enzymatic and dependent on the hepatic enzyme rhodenase. Thiocyanate is then oxidized to cyanide by a thiocyanate oxidase contained in the red cells (Page et al. 1955) . To restore normal levels of blood pressure in hypotensive states produced by this agent it is usually only necessary to discontinue its administration. Should an even more rapid rise in blood pressure be required during the period of action of the drug, peripheral vasoconstrictors would of course be ineffective and an agent with direct myocardial action would be needed.
Following the comments of Jones & Cole (1968), drawing fresh attention to sodium nitroprusside, Taylor et al. (1970) described 83 experiences with the drug and mentioned an additional 25 cases. My own experience so far extends to a mere 40 cases. Even at this early stage it does appear to be a drug with considerable potential.
In a limited use, I have found it to behave in a predictable manner, producing a well-defined fall in blood pressure to any desired level, relatively easy maintenance at that level, and rapid recovery on ending its administration. Its apparent advantages over trimetaphan are that tachyphylaxis is not a problem, the absence of histamine release, the very short duration of action, and its low cost.
The level of blood pressure achieved is dependent on the rate of drug administration and Taylor et al. (1970) have rightly drawn attention to the main difficulty encountered in its use, namely the maintenance of a suitable drip speed with conventional drip sets. There is, however, no need, as there is with trimetaphan, to employ concentrated solutions to avoid frequent tachyphylaxis. It is much easier to vary rates of drug administration by using a weak solution and a relatively rapid drip rate. In any case the commonly recommended drip strength of 0-01% sodium nitroprusside appears unnecessarily strong for all but the youngest and fittest of patients. Table 1 shows drip strengths which are suggested as guidelines for clinical usage. Patients on the borders of the groups may be moved from one to another according to physical fitness or debility.
Sodium nitroprusside is the latest drug to come on the hypotensive scene for use in such techniques as middle ear surgery. However, it is no new drug. It was initially described in 1849 by Playfair, and in 1929 its hypotensive action was reported (Johnson 1929) . In 1955 Page et al. described its actions and uses in lowering blood pressure, and its administration to patients who were given large oral doses for up to two years. Blood thiocyanate levels of 8-12 mg/100 ml were maintained with no serious side-effects. He also reported its use in drip form for the treatment of hypertensive crises. Used as a drip in anmsthetic practice, it has been shown that the highest blood levels attained are of the order of 0 05 mg/100 ml (Jones & Cole 1968).
The failure of sodium nitroprusside to find favour in presentday practice cannot be attributed to its inability to produce the desired effect. Rather, disillusion may have followed a belief that its action is too evanescent for clinical usage. In anesthesia such brevity of action could be considered a positive virtue. It is heartening for the clinician that even today, with all the efficient machinery of research, it is possible to find in the literature a drug whose virtues have for so long been largely unappreciated. Sodium nitroprusside is not yet available commercially, so solutions must be made up by hospital pharmacies. Several points require comment: (1) Solutions of the drug must be sterilized by filtration, a suitable millipore filter being recommended for this purpose (Taylor et al. 1970 ). (2) Its shelf life is prolonged up to at least three months if it is stored in a refrigerator. Fortunately, any degeneration is accompanied by a colour change from browny-pink to blue.
(3) As the solution is usually prepared in distilled water at pH 5 5 it would seem sensible to employ an infusion fluid with approximately the same pH; a dextrose saline solution meets this requirement.
